Autoimmune Technologies, LLC

UEI
NBLGCCAQXG85
CAGE
4CV15
Primary NAICS
541714 Research and Development in Biotechnology (except Nanobiotechnology)
SAM.gov registration
Expired

Company facts

Self-certified in SAM.gov
  • For Profit Organization
  • Limited Liability Company
Entity structure
Partnership or Limited Liability Partnership
SAM.gov registration date
Website
autoimmune.com
Employees
1-10
Estimated annual revenue
$1M-$10M
Industry
  1. Health Care
  2. Pharmaceuticals, Biotechnology & Life Sciences
  3. Pharmaceuticals
SIC code
28 Chemical & Allied Products
Profiles

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Contract awards

Award Agency Obligated Awarded
Development of therapeutic medical countermeasures for biodefense and emerging infectious disease HHSN272201400003C National Institute of Allergy and Infectious Diseases (NIH) $14,754,660

Grant awards

Award Agency Obligated Awarded
Double chimeric peptide vaccine feasible for human use that protects against disseminated candidiasis caused by… R41AI138722 National Institute of Allergy and Infectious Diseases (NIH) $224,645
Development of an immunotherapeutic delivery platform using adipose-derived mesenchymal stem cells W81XWH1710063 Medical Command (Army) $239,903
Peptide inhibitors of coronavirus entry R43AI112221 National Institutes of Health $225,000
Peptide inhbitors of influenza entry-fast track R44AI082778 National Institutes of Health $3,938,686
Peptide drugs against influenza virus R41AI068230 National Institutes of Health $461,944

Quick answers

Is Autoimmune Technologies, LLC registered in SAM.gov?

Autoimmune Technologies, LLC's SAM.gov registration expired on February 16, 2025.

What is Autoimmune Technologies, LLC's CAGE code?

Autoimmune Technologies, LLC's CAGE code is 4CV15, and its Unique Entity ID (UEI) is NBLGCCAQXG85.

What is Autoimmune Technologies, LLC's most recent federal award?

Autoimmune Technologies, LLC's most recent federal grant award is Double chimeric peptide vaccine feasible for human use that protects against disseminated candidiasis caused by… (R41AI138722), from National Institute of Allergy and Infectious Diseases (NIH), on August 13, 2018.

On GovTribe

See Autoimmune Technologies, LLC's full federal record

  • Federal contract awards
  • Federal grant awards
  • Subcontracting relationships
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors
Try for free Login

Find teaming partners on GovTribe